Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressConvertible DebtCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Heron Therapeutics (HRTX) Short-term Investments (2016 - 2025)

Heron Therapeutics (HRTX) has disclosed Short-term Investments for 10 consecutive years, with $12.4 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Short-term Investments fell 72.49% year-over-year to $12.4 million, compared with a TTM value of $12.4 million through Sep 2025, down 72.49%, and an annual FY2024 reading of $33.5 million, down 35.28% over the prior year.
  • Short-term Investments was $12.4 million for Q3 2025 at Heron Therapeutics, down from $24.1 million in the prior quarter.
  • Across five years, Short-term Investments topped out at $106.7 million in Q1 2021 and bottomed at $12.4 million in Q3 2025.
  • Average Short-term Investments over 5 years is $47.8 million, with a median of $45.1 million recorded in 2024.
  • The sharpest move saw Short-term Investments crashed 73.47% in 2021, then soared 147.5% in 2024.
  • Year by year, Short-term Investments stood at $67.0 million in 2021, then increased by 3.65% to $69.5 million in 2022, then dropped by 25.55% to $51.7 million in 2023, then tumbled by 35.28% to $33.5 million in 2024, then crashed by 62.91% to $12.4 million in 2025.
  • Business Quant data shows Short-term Investments for HRTX at $12.4 million in Q3 2025, $24.1 million in Q2 2025, and $31.4 million in Q1 2025.